() -Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA ​medicines in the U., marking a major ‌step in strengthening the company's domestic production network.

(Reuters) -Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to ​resolve a lawsuit claiming they defrauded the state's Medicaid program ‌over alleged quality control lapses in a medicine to treat attention deficit hyperactivity disorder in ‌children.

ZURICH () -Novartis will expand its operations in North Carolina and build a ​manufacturing hub there as part of a planned ‌$23 billion of U. infrastructure investment over the next ‌five years, the Swiss pharmaceuticals company said on Wednesday.

(Reuters) -Merck said on Monday it expects a commercial opportunity exceeding $5 billion from ​Cidara Therapeutics' experimental flu drug, and does not anticipate ‌it to require a review by the U. CDC's vaccine advisory panel before ‌launch.

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy the drugs directly.

COPENHAGEN (Reuters) -Novo Nordisk said on Monday it would lower the U. price of its injectable Wegovy obesity drug and pledged to go "all in" on its upcoming oral weight-loss pill,​ as the firm races to claw back lost ground in the lucrative market.

Comet 3I/ATLAS recently emerged from behind the glare of the sun to become visible to ground-based telescopes.

Robert Hays, an industrial electronics salesman in Arkansas, thought he’d purchased conventional medical insurance. So did Essie Nath, 67, a retired cafeteria worker in Wyoming. So did Martin Liz, 47, a Key West chef. Each enrolled in the kind of private health insurance that Trump administration officials have promoted as an alternative to plans sold under Obamacare.Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. The difference betw

New versions of Cheetos and Doritos, without artificial flavors or dyes, will be sold in December.

The Food and Drug Administration said Friday it will add a new warning and other limitations to a gene therapy for Duchenne’s muscular dystrophy that's been linked to two patient deaths. The infused therapy from Sarepta Therapeutics will carry a boxed warning — the most serious type — alerting doctors and patients to the risk of potentially fatal liver failure with the treatment, the FDA said in a release. The one-time therapy, Elevidys, has been under FDA scrutiny since the company reported t

New versions of Cheetos and Doritos, without artificial flavors or dyes, will be sold in December.

The Food and Drug Administration said Friday it will add a new warning and other limitations to a gene therapy for Duchenne’s muscular dystrophy that's been linked to two patient deaths. The infused therapy from Sarepta Therapeutics will carry a boxed warning — the most serious type — alerting doctors and patients to the risk of potentially fatal liver failure with the treatment, the FDA said in a release. The one-time therapy, Elevidys, has been under FDA scrutiny since the company reported t

Doritos and Cheetos are getting a makeover. PepsiCo said Thursday it’s launching toned-down versions of its bright orange snacks that won't have any artificial colors or flavors. Doritos and Cheetos Simply NKD will hit store shelves on Dec. 1.

By Kamal Choudhury and Christy Santhosh (Reuters) -The U. Food and Drug Administration on Thursday approved Kura Oncology and Japanese ​partner Kyowa Kirin's once-daily pill, Komzifti, to treat a ‌rare form of blood cancer that has returned or stopped responding to treatment.

PepsiCo announced on Thursday that its Cheetos and Doritos brands will be offering "colorless" alternatives

Germany's Federal Court of Justice (BGH) is set to rule on Thursday on claims by Wirecard shareholders in the insolvency of the former DAX company. The question at issue is whether aggrieved shareholders can claim damages from the insolvency estate as ordinary creditors or not.

By Sneha S K and Sriparna Roy (Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes,​ including a potential sale, and warned it could launch a proxy fight if no progress ‌is made in the next four months. In a second letter to Novavax's board in less than a month, shared exclusively with ‌Reuters on Wednesday, Shah Capital said it has become "increasingly disenchanted" with the company's weak COVID-19 vaccine sales.

By Jonathan Stempel NEW YORK (Reuters) -Amazon.com was sued on Wednesday in a proposed class action saying the retailer subjects thousands of warehouse employees with disabilities to a "punitive"

By Jonathan Stempel NEW YORK (Reuters) -Amazon.com was sued on Wednesday in a proposed class action saying the retailer subjects thousands of warehouse employees with disabilities to a "punitive"